Merck said its pivotal Phase 3 TroFuse-015 trial of sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate licensed from China's Kelun-Biotech, met its primary endpoint of overall survival (OS) in patients with previously treated gastroesophageal adenocarcinoma, according to a company announcement. Merck also disclosed that the drug missed a secondary endpoint of progression-free survival (PFS) — a split outcome that RBC Capital Markets analysts, in a Friday morning note to investors cited by BioSpace, called "not unheard of in oncology trials," adding that OS "remains the gold standard in these settings."
What the Trial Showed
TroFuse-015 tested sac-TMT against treatment of physician's choice (TPC) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received two or more prior lines of systemic therapy. TPC in the trial consisted of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. At final analysis, Merck said sac-TMT produced a statistically significant and clinically meaningful improvement in OS compared with TPC, though neither Merck nor Kelun-Biotech disclosed the underlying hazard ratio, p-value or median OS figures. The company said sac-TMT did not meet the secondary endpoint of PFS as assessed by blinded independent central review, while objective response rate showed a nominally improved benefit favoring sac-TMT that was not formally tested under the prespecified analysis plan. Results were generally consistent across subgroups regardless of TROP2 expression status, according to Merck, which described TroFuse-015 as the first time a TROP2-directed ADC has demonstrated an OS benefit in a global Phase 3 trial in this heavily pretreated population, and as the second positive Phase 3 readout from a TroFuse program that now comprises 18 ongoing global Phase 3 trials across multiple tumor types. Bottom line: the readout is a win on the endpoint regulators weigh most heavily, but with no effect size disclosed and PFS missed, interpretation of the result's commercial significance — including the $4.3 billion peak-sales projection for sac-TMT that BMO analysts published in a September report, per BioSpace — depends on detailed data Merck has not yet released.
DISCLAIMER: Traders Agency does not offer financial advice. The information provided is for educational purposes only and should not be considered financial advice. Traders Agency is not responsible for any financial losses or consequences resulting from the use of the information provided. Trading carries inherent risks and may not be suitable for all individuals. You are advised to conduct your own research and seek personalized advice before making any investment decisions, recognizing the potential risks and rewards involved.
- Seeking Alpha Market News: Merck · accessed Nov 20, 2026
- Merck: Merck Announces TroFuse-015 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoint of Overall Survival (OS) in Third-Line or Later Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma - Merck.com · accessed Nov 20, 2026
- BioSpace: Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial · accessed Nov 20, 2026
- U.S. Securities and Exchange Commission: Merck & Co., Inc. — Third-quarter 2022 Form 10-Q, acquisitions, research collaborations and license agreements · accessed Nov 20, 2026
See more from Traders Agency on Google
Make us a preferred source and our market analysis will appear more prominently in your Google Search, Top Stories, and AI results.
Add to Preferred Sources




